Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

71.72 +0.57 (+0.80%)
Streaming Delayed Price Updated: 11:44 AM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever
In a frothy market starved for value, these three dividend stocks combine reasonable valuations with the proven ability to disrupt themselves. 
Via The Motley Fool
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug. 
Via MarketBeat
Exposures COVID-19
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%. 
Via Benzinga
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder. 
Via Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Investing in the most popular players in the space isn't the only valid approach. 
Via The Motley Fool
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Lower; Dow Tumbles Over 150 Points
Via Benzinga
Topics Stocks
Exposures US Equities
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise in a... 
Via Benzinga
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
From AstraZeneca
Via Business Wire
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization... 
Via Benzinga
Exposures Product Safety
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
AstraZeneca's Calquence receives FDA Priority Review for previously untreated mantle cell lymphoma, showing promising Phase 3 trial results in reducing disease progression by 27%. An FDA decision is... 
Via Benzinga
Exposures Product Safety
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
From AstraZeneca
Via Business Wire
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
Exposures Interest Rates
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
Via News Direct
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
From AstraZeneca
Via Business Wire
Is Summit Therapeutics Stock a Buy?
Its alliance with a successful foreign biotech could be decisive for the stock. 
Via The Motley Fool
Week In Review: Zenas Raises $259 Million In IPO
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Top Stock Reports For Toyota, AstraZeneca & Chubb
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp., AstraZeneca PLC, and Chubb Ltd., as well as two micro-cap stocks Air T, Inc. and Preformed Line... 
Via Talk Markets
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, showcasing significant improvements in progression-free survival rates. 
Via Benzinga
Exposures Product Safety
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows... 
Via Benzinga
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment. 
Via Investor's Business Daily
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2024 Diversified Communications. All rights reserved.